<div id="readability-page-1"><p><span>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report)</span>'s stock had its &#34;outperform&#34; rating reissued by Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $94.00 target price on the biotechnology company's stock. Wedbush's target price points to a potential upside of 51.02% from the stock's current price.</p><ul><li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li></ul><p>A number of other equities research analysts also recently issued reports on the stock. Wolfe Research  set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, July 15th. Wall Street Zen cut shares of BioMarin Pharmaceutical from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. The Goldman Sachs Group dropped their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, May 5th. Morgan Stanley reduced their target price on BioMarin Pharmaceutical from $97.00 to $96.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, July 22nd. Finally, JPMorgan Chase &amp; Co. increased their price objective on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, July 14th. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned  a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $93.78.</p><p><b>Get Our Latest Stock Analysis on BMRN</b></p><h2>BioMarin Pharmaceutical Price Performance</h2><ul><li>3 Oversold Stocks with Big RSI Rebound Potential</li></ul><p>BMRN traded up $1.93 during trading on Tuesday, reaching $62.24. 1,233,643 shares of the stock were exchanged, compared to its average volume of 1,887,433. The company has a market capitalization of $11.94 billion, a price-to-earnings ratio of 23.21, a P/E/G ratio of 0.80 and a beta of 0.18. BioMarin Pharmaceutical has a 1 year low of $52.93 and a 1 year high of $94.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.52 and a quick ratio of 3.49. The business's 50 day moving average price is $57.16 and its two-hundred day moving average price is $61.79. </p><h2>Insider Transactions at BioMarin Pharmaceutical</h2><p>In related news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares of the company's stock, valued at $840,600.63. The trade was a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own  0.85% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><ul><li>Are Gene Therapy Stocks The Market's Next Big Winners?</li></ul><p>A number of hedge funds have recently bought and sold shares of the company. Rise Advisors LLC purchased a new position in  BioMarin Pharmaceutical during the first quarter valued at $30,000.  Farther Finance Advisors LLC grew its stake in  BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after buying an additional 211 shares during the period.  V Square Quantitative Management LLC bought a new position in  BioMarin Pharmaceutical in the 2nd quarter valued at about $25,000.  LRI Investments LLC boosted its stake in shares of  BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 437 shares in the last quarter.  Finally, MassMutual Private Wealth &amp; Trust FSB lifted its position in  BioMarin Pharmaceutical by 71.2% during the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 218 shares during the period. 98.71% of the stock is currently owned by institutional investors. </p><h2>About BioMarin Pharmaceutical</h2> (Get Free Report)<p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than BioMarin Pharmaceutical</li><li>Following Congress Stock Trades</li><li>Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?</li><li>3 Warren Buffett Stocks to Buy Now</li><li>META Gets Huge Upgrades: How High Analysts Think Shares Could Go</li><li>Investing in Travel Stocks Benefits</li><li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BMRN

<p>Wedbush has reiterated an "outperform" rating for BioMarin Pharmaceutical (BMRN) with a target price of $94.00, indicating a potential upside of 51.02%. Other analysts have also provided ratings, with Wolfe Research setting a $95.00 target and Goldman Sachs adjusting theirs to $104.00. The stock is currently trading at $62.24, with a consensus rating of "Moderate Buy" and an average price target of $93.78. BioMarin specializes in therapies for rare diseases and has a market cap of $11.94 billion.</p>

BioMarin Pharmaceutical's (BMRN) "Outperform" Rating Reiterated at Wedbush